- Home
- TSVT vs AARD Comparison
TSVT vs AARD Comparison
Compare TSVT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- AARD
- Stock Information
- Founded
- TSVT 2021
- AARD 2017
- Country
- TSVT United States
- AARD United States
- Employees
- TSVT N/A
- AARD N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- AARD Health Care
- Exchange
- TSVT Nasdaq
- AARD Nasdaq
- Market Cap
- TSVT 258.9M
- AARD 216.6M
- IPO Year
- TSVT N/A
- AARD 2025
- Fundamental
- Price
- TSVT $4.95
- AARD $7.74
- Analyst Decision
- TSVT Buy
- AARD Strong Buy
- Analyst Count
- TSVT 5
- AARD 4
- Target Price
- TSVT $7.60
- AARD $31.50
- AVG Volume (30 Days)
- TSVT 2.5M
- AARD 113.5K
- Earning Date
- TSVT 03-25-2025
- AARD 01-01-0001
- Dividend Yield
- TSVT N/A
- AARD N/A
- EPS Growth
- TSVT N/A
- AARD N/A
- EPS
- TSVT N/A
- AARD N/A
- Revenue
- TSVT $37,862,000.00
- AARD N/A
- Revenue This Year
- TSVT $72.76
- AARD N/A
- Revenue Next Year
- TSVT $25.59
- AARD N/A
- P/E Ratio
- TSVT N/A
- AARD N/A
- Revenue Growth
- TSVT N/A
- AARD N/A
- 52 Week Low
- TSVT $2.29
- AARD $7.74
- 52 Week High
- TSVT $5.99
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TSVT 80.79
- AARD N/A
- Support Level
- TSVT $2.55
- AARD N/A
- Resistance Level
- TSVT $4.97
- AARD N/A
- Average True Range (ATR)
- TSVT 0.01
- AARD 0.00
- MACD
- TSVT -0.00
- AARD 0.00
- Stochastic Oscillator
- TSVT 60.00
- AARD 0.00
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.